Brought to you by 
Pediatric drug maker Pernix Therapeutics nets $19.7mm in RDO
13 Oct 2011
Executive Summary
Pernix Therapeutics Holdings Inc. (branded and generic pediatric products for allergy, upper respiratory conditions, infectious disease, and dermatological disorders) netted $19.7mm in a registered direct offering of 3mm shares at $7 (a 22% discount). Aisling Capital and OrbiMed Advisors were the lead investors. Pernix’s management and board also sold 1mm shares in the RDO (but the company will not realize any of those proceeds).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pediatric drug maker Pernix Therapeutics nets $19.7mm in RDO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice